News

  • 8 May 2019

    Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA) today reported the Company’s financial results for the first quarter of 2019.

  • 8 May 2019

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, reported today financial results for the first quarter ended March 31, 2019, and provided an update on operational initiatives.

  • 6 May 2019

    Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, announced the presentation of positive results from the ARTISAN-SNM pivotal study, designed to gain market approval from the U.S. Food & Drug Administration (FDA) for the Axonics r-SNM® System1.

  • 6 May 2019

    Index provided a status update on the patient recruitment in the CONDUCT study. “With only 10 patients left to enrol we estimate that the patient recruitment will be completed during the month of June at the latest,” said Peter Zerhouni, CEO of InDex Pharmaceuticals.

  • 2 May 2019

    Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX) announced today top-line efficacy data for its NOX1/4 inhibitor GKT831 Phase 2 trial in primary biliary cholangitis (PBC). In a pre-defined patient population with an estimated liver fibrosis stage of F3 or higher, GKT831 achieved a 22% reduction in liver stiffness compared to a 4% increase for placebo (p=0.038). The top-line data provide a clinical proof of concept for GKT831 and highlight its potential as an anti-fibrotic therapy in the liver and other organs. Further analyses are ongoing and the full results will be submitted for presentation at an upcoming international liver conference.